CTOs on the Move

Michigan Medicine

www.med.umich.edu

 
Michigan Medicine, based in Ann Arbor, Michigan, is part of one of the world`s leading universities. Michigan Medicine is a premier, highly ranked academic medical center and award-winning health care system with state-of-the-art facilities. Our vision is to create the future of health care through scientific discovery, innovations in education, and the most effective and compassionate care.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.med.umich.edu
  • 1500 E Medical Center Dr
    Ann Arbor, MI USA 48109
  • Phone: 734.936.4000

Executives

Name Title Contact Details

Similar Companies

Ambient Eco Group

Ambient Eco Group is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EMD Biosciences

EMD Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunicom

Immunicom, Inc. is a privately held medical technology company that develops subtractive therapies for cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom`s blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types and other terminal diseases with a safer side-effect profile than conventional treatments. Immunicom`s lead product, the LW-02 column, previously received FDA Breakthrough Device designation in 2018 for stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in adults with advanced, refractory, triple negative breast cancer. Immunopheresis is being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.

Cleartrails

Cleartrails is a Villa Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fusion Pharmaceuticals

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion`s lead program, FPI-1434, is currently in a Phase 1 clinical trial. Fusion is headquartered in Hamilton, ON, with offices in Boston, MA.